Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 4
1968 5
1969 6
1970 9
1971 13
1972 17
1973 23
1974 27
1975 16
1976 25
1977 31
1978 38
1979 18
1980 15
1981 17
1982 14
1983 13
1984 15
1985 14
1986 5
1987 4
1988 8
1989 11
1990 3
1991 5
1992 5
1993 3
1994 10
1995 6
1996 17
1997 8
1998 11
1999 20
2000 17
2001 24
2002 27
2003 45
2004 47
2005 37
2006 50
2007 50
2008 43
2009 53
2010 69
2011 62
2012 48
2013 59
2014 82
2015 69
2016 70
2017 71
2018 70
2019 23
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,351 results
Results by year
Filters applied: . Clear all
Page 1
Targeting Huntingtin Expression in Patients with Huntington's Disease.
Tabrizi SJ, et al. N Engl J Med 2019 - Clinical Trial. PMID 31059641
BACKGROUND: Huntington's disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat expansion in HTT, resulting in a mutant huntingtin protein. ...METHODS: We conducted a randomized, double-blind, multiple-ascending-dose, phase 1-2a trial involving adults with early Huntington's disease. ...
BACKGROUND: Huntington's disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat …
Therapeutic approaches to Huntington disease: from the bench to the clinic.
Caron NS, et al. Nat Rev Drug Discov 2018 - Review. PMID 30237454
The 25 years since the identification of the gene responsible for Huntington disease (HD) have stood witness to profound discoveries about the nature of the disease and its pathogenesis. Despite this progress, however, the development of disease-modifying therapies has thus far been slow. Preclinical validation of the therapeutic potential of disrupted pathways in HD has led to the advancement of pharmacological agents, both novel and repurposed, for clinical evaluation. ...
The 25 years since the identification of the gene responsible for Huntington disease (HD) have stood witness to profound disco …
iPSC-based drug screening for Huntington's disease.
Zhang N, et al. Brain Res 2016 - Review. PMID 26428226 Free PMC article.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by an expansion of the CAG repeat in exon 1 of the huntingtin gene. ...Since the original identification of the Huntington disease associated gene, in 1993, a variety of models have been created and used to advance our understanding of HD. ...
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by an expansion of the CAG repeat in exo
Insights into GABA(A)ergic system alteration in Huntington's disease.
Hsu YT, et al. Open Biol 2018 - Review. PMID 30518638 Free PMC article.
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disease that is characterized by a triad of motor, psychiatric and cognitive impairments. There is still no effective therapy to delay or halt the disease progress. The striatum and cortex are two particularly affected brain regions that exhibit dense reciprocal excitatory glutamate and inhibitory gamma-amino butyric acid (GABA) connections. ...
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disease that is characterized by a tri
Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.
Loi SM, et al. Australas Psychiatry 2018 - Review. PMID 29687724
OBJECTIVES: This clinical update review focuses on the management of the neuropsychiatric manifestations of Huntington's disease (HD). ...
OBJECTIVES: This clinical update review focuses on the management of the neuropsychiatric manifestations of Huntington's disease
Cognitive assessment in Huntington disease clinical drug trials.
Stout JC, et al. Handb Clin Neurol 2017 - Review. PMID 28947120
Several Huntington disease (HD) clinical trials are in progress and on the horizon. Potential treatments are increasingly being targeted at ameliorating the cognitive decline in HD. ...We evaluate strategies for selecting cognitive tools for HD clinical trials, and consider cognitive assessments that have been used in other neuropsychiatric disorders, namely Alzheimer disease and schizophrenia. ...
Several Huntington disease (HD) clinical trials are in progress and on the horizon. Potential treatments are increasingly bein …
The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
Maher P. Int J Mol Sci 2019 - Review. PMID 31234550 Free PMC article.
Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. ...
Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease ( …
Medical treatment of behavioral manifestations of Huntington disease.
van Duijn E. Handb Clin Neurol 2017 - Review. PMID 28947111
Almost all patients with Huntington disease (HD) show some form of behavioral changes during the disease progression. These behavioral manifestations may already be present before cognitive or motor symptoms become apparent, and vary from subtle anxiety to severe psychosis and suicide attempts. These behavioral manifestations are related to both psychologic factors, like the burden of having a severe disease, and biologic factors that are related to the disease itself. ...
Almost all patients with Huntington disease (HD) show some form of behavioral changes during the disease progression. T …
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Huntington Study Group , et al. JAMA 2016 - Clinical Trial. PMID 27380342 Free article.
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. ...CONCLUSIONS AND RELEVANCE: Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. ...
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. …
Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases
Yang X, et al. Curr Top Med Chem 2016 - Review. PMID 26311425
In addition, the effects of CoQ10 on Alzheimer's disease, Parkinson's disease, and Huntington's disease are also discussed. Finally, future perspectives regarding development of successful treatment for neurodegenerative diseases are proposed....
In addition, the effects of CoQ10 on Alzheimer's disease, Parkinson's disease, and Huntington's disease are also …
1,351 results
Jump to page
Feedback